Insulin-like Growth Factor 1

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone primarily produced in the liver, with additional synthesis occurring in various tissues, including skeletal muscle and the brain. Researchers primarily study IGF-1 for its critical role in growth, metabolism, and cellular repair processes. Key findings indicate that IGF-1 signaling is involved in glucose metabolism, particularly in conditions like colorectal cancer, where it may influence the Warburg effect, and in skeletal muscle, where it regulates protein synthesis and inhibits atrophy. Additionally, studies suggest that IGF-1 deficiency is common in chronic conditions such as cirrhosis, contributing to malnutrition and increased liver vulnerability. Current research continues to explore the multifaceted roles of IGF-1 in health and disease, highlighting its potential as a biomarker and therapeutic target in various clinical contexts.

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C or Mecasermin, is an endogenous peptide hormone primarily produced in the liver, although it is also synthesized in other tissues in response to growth hormone (GH) stimulation. It belongs to the chemical class of growth factors and plays a crucial role in growth and development. IGF-1 is structurally similar to insulin and is involved in cell growth, differentiation, and survival. Researchers have extensively studied IGF-1 for its role in various physiological processes and pathological conditions. It is known to regulate glucose metabolism, skeletal muscle hypertrophy, and atrophy, and is implicated in cancer biology, particularly colorectal cancer, where it influences glucose uptake and the Warburg effect. IGF-1 acts through the IGF-1 receptor (IGF-1R), activating pathways such as PI3K/Akt/mTOR and MAPK, which are critical for its biological effects. These pathways facilitate protein synthesis, inhibit protein degradation, and modulate autophagy, thereby influencing muscle growth and regeneration. Pharmacokinetically, the endogenous half-life of IGF-1 is approximately 12-15 hours, with metabolism primarily occurring in the liver. The bioavailability of synthetic forms like Mecasermin varies by administration route, with subcutaneous administration being common. Clinically, IGF-1 is used in the treatment of growth failure in children with severe primary IGF-1 deficiency. It is regulated as a prescription medication and is prohibited in sports by the World Anti-Doping Agency due to its performance-enhancing potential.

IGF-1 acts primarily through the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor, initiating signaling cascades such as the PI3K/Akt/mTOR and MAPK pathways. These cascades promote cellular growth, proliferation, and survival by enhancing protein synthesis and inhibiting apoptosis and protein degradation.

Insulin-like Growth Factor 1 (IGF-1) primarily exerts its effects through the IGF-1 receptor (IGF-1R), activating downstream signaling pathways such as PI3K/Akt/mTOR and Raf/MAPK. These pathways are involved in promoting anabolic processes like protein synthesis in skeletal muscle, enhancing glucose uptake via glucose transporters (e.g., GLUT1), and regulating glycolytic enzymes, while also inhibiting catabolic pathways, including the ubiquitin-proteasome system and autophagy. Although the precise mechanisms linking IGF-1 to various biological processes, including cancer metabolism and muscle hypertrophy, remain incompletely understood, its role in mediating cellular growth and metabolism is well established.

Current evidence is limited regarding the specific mechanisms by which IGF-1 interacts with metabolic syndrome and colorectal cancer, particularly in the context of the Warburg effect and its regulation of glucose metabolism. Further research is needed to elucidate the role of IGF-1 in muscle atrophy and hypertrophy, especially concerning the contribution of autophagy and miRNA regulation in various pathological conditions. Additionally, the therapeutic potential of IGF-1 replacement in cirrhosis requires larger randomized controlled trials to assess long-term efficacy and safety in diverse patient populations.